A BCG hydrogel enables localized NOD2/STING activation to overcome resistance to immune checkpoint blockade

Z Ziyuan Xiao (Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University) H Huizhen Xu (Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University) N Ningyi Ma (Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University) L Lei Lei (Department of Molecular, Cell and Developmental Biology, University of California) C Chunyu Cong (Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University) N Ningyi Sun (Department of Clinical Microbiology, School of Laboratory Medicine, Chengdu Medical College) G Guodong Wang (Key Laboratory of Seed Innovation, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences) X Xingmei Chen (Materials Research Laboratory, University of Illinois at Urbana-Champaign) K Ke Ren H Haishi Qiao (Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University)

Abstract

Resistance to immune checkpoint blockade (ICB) often arises from immunologically cold tumors enriched in suppressive myeloid cells. Previous studies have implicated NOD2 signaling in antitumor immunity and in modulation of ICB responses, but approaches to engage this pathway effectively and durably within tumors remain limited. Here, single-cell transcriptomic analysis of colorectal cancer identified a NOD2 high tumor-associated macrophage (TAM) subset enriched for inflammatory and immune-activating programs. To therapeutically harness this state, we engineered an injectable manganese-containing alginate hydrogel encapsulating polyarginine-functionalized Bacillus Calmette-Guérin (MHY@PBCG) for sustained intratumoral delivery and localized coactivation of NOD2 and STING signaling in TAMs. Polyarginine enhanced BCG uptake by macrophages, whereas Mn 2+ stabilized the hydrogel and amplified STING activation. Local administration of MHY@PBCG reprogrammed TAMs toward an M1-like phenotype, increased inflammatory cytokine and interferon programs, converted cold tumors into immune-inflamed lesions, and restored responsiveness to anti-PD1 therapy in multiple models. Mechanistically, coordinated NOD2/STING activation established a self-reinforcing inflammatory circuit linking macrophage reprogramming to downstream T cell–mediated antitumor immunity. These findings establish a localized biomaterial strategy for overcoming checkpoint resistance through macrophage-centered remodeling of the tumor microenvironment.

Article Details

Volume / Issue Vol. 123, Issue 21
Published May 26, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (10)

Z

Ziyuan Xiao

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University

H

Huizhen Xu

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University

N

Ningyi Ma

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University

L

Lei Lei

Department of Molecular, Cell and Developmental Biology, University of California

C

Chunyu Cong

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University

N

Ningyi Sun

Department of Clinical Microbiology, School of Laboratory Medicine, Chengdu Medical College

G

Guodong Wang

Key Laboratory of Seed Innovation, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences

X

Xingmei Chen

Materials Research Laboratory, University of Illinois at Urbana-Champaign

K

Ke Ren

H

Haishi Qiao

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University